fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: they will receive the drug Dapagliflozin 10 mg daily for 90 days, produced by Medava Pharmaceutical Company, Tehran, Iran. Intervention 2: Contr
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Individuals from the general population aged between 20 and 65 years A controlled attenuation parameter (CAP) greater than or equal to 238dB/m in the liver fiber scan test
Exclusion criteria
Exclusion criteria: Known diseases including:Type 1 or 2 diabetes, acute or chronic liver disease, biliary tract disease, kidney or heart failure, active cancer or anticancer treatment within the past two years, untreated thyroid disease History of alcohol consumption drugs related to fatty liver such as continuous and daily use of non-steroidal anti-inflammatory drugs, amiodarone, tamoxifen, sodium valproate, methotrexate and corticosteroids, other drugs that affect fatty liver such as vitamin E and pioglitazone use of supplements such as vitamin C in the last month cardiovascular events in the last three months, pregnancy and breastfeeding, BMI greater than or equal to 40 kg/m2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of liver fat using controlled attenuation parameter. Timepoint: At the beginning of the study and after 3 months of treatment with dapagliflozin tablets or placebo. Method of measurement: Using liver fibroscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measuremnet of Chol. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of FBS. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of Controlled attenuation parameter. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using liver fibroscan.;Measurement of CBC/diff. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of ALT,. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of AST. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of HDL. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of LDL. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods.;Measurement of TG. Timepoint: At the beginning of the study and 3 months after the start of treatment. Method of measurement: Using laboratory methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Mazloum Khorasani
Mashhad University of Medical Sciences
Outcome results
None listed